13th Conference on Retroviruses and Opportunistic Infections Denver, Colorado - February 5-8, 2006

Conf Retrovir Opportunistic Infect 2006 Feb 5-8;13:abstract no. 56

Lawrence Corey
HIV Vaccine Trials Network, Fred Hutchinson Cancer Res Ctr, Seattle, US

BACKGROUND: Development of an HIV vaccine is a public health priority. A variety of non-human primate studies have indicated that both neutralizing antibodies and adaptive T cell responses, especially CD8⁺ T cell responses, can prevent experimental challenge and/or control viremia post-experimental infection with primate lentiviruses. The recent failure of monomeric gp120 vaccines has been a vivid demonstration of the need to develop new approaches to elicit neutralizing antibodies to circulating strains of HIV-1. At present, most of the emphasis on HIV vaccines has therefore been directed at approaches to induce HIV-1 CD8⁺ T cells and to evaluate whether such responses can reduce set-point viremia and potentially secondary transmission of the virus to others. In non-human primates, a sustained reduction in set-point viremia has been produced by vaccination with a variety of DNA and viral vector based vaccines. Human clinical trials of both DNA vaccines and poxvirus vectors have had, in most cases, disappointing immunogenicity, albeit 1 phase 3 trial of a canarypox clade B/E vaccine is being conducted in Thailand. To date the most immunogenic cytotoxic leukocyte (CTL)-inducing vaccine approaches have utilized recombinant replication defective adenovirus.

CONCLUSIONS: The 2 leading candidates are a recombinant Ad5 vector containing gag-pol-nef made by Merck Corporation, and a multivalent DNA followed by Ad5 vaccine made by the NIH Vaccine Research Center. These vaccines are entering advanced clinical trials and a review of their immunogenicity and approaches to evaluate their potential efficacy in humans will be discussed.

Download abstract

2006-02-05
56

Copyright © 2006 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health.